Polyionic Papillomavirus VLPs for Expanded Epitope Insertion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to generating potent virus-like particle (VLP) vaccines face limitations in expanding their application due to constraints in the size and nature of epitopes that can be inserted, necessitating the development of novel methods for enhancing immunological properties.
Innovation Solution
The creation of chimeric papillomavirus VLPs with a L1 protein that includes negatively charged amino acids, specifically in the HI loop, and the conjugation of these VLPs with target antigens using a polyionic approach, which activates antigen-presenting cells and induces robust immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If fusion proteins of VLP protein and candidate vaccine peptide are constructed, then VLP vaccines can be generated, but the size and nature of epitopes that can be inserted are limited
Solution Approach 1:
The invention divides the VLP structure into modular components, specifically utilizing the HI loop region as a distinct segment for epitope insertion. This segmentation allows independent optimization of the VLP core structure and the inserted epitope, enabling insertion of larger and more diverse epitopes without compromising overall VLP assembly and stability.
Solution Approach 2:
The invention applies local quality by concentrating epitope insertion efforts specifically in the HI loop region rather than attempting uniform modifications throughout the VLP structure. This localized approach allows for targeted insertion of diverse epitopes while maintaining the structural integrity and self-assembly capabilities of the L1 protein core.
2Reliability
If polyionic amino acids are inserted into VLPs, then immunological properties are enhanced, but manufacturing complexity increases
Solution Approach 1:
The invention changes the chemical parameters of the VLP surface by inserting polyionic amino acid sequences (such as polyglutamic acid or polyaspartic acid) into the HI loop. This parameter change introduces negative charges that enhance immunogenicity through electrostatic interactions with antigen-presenting cells, while the insertion is achieved through straightforward molecular cloning techniques that do not significantly complicate manufacturing.
Solution Approach 2:
The invention creates composite structures by combining the L1 protein framework with polyionic amino acid sequences. This composite approach integrates the structural benefits of the L1 protein with the immunological advantages of polyionic sequences, resulting in VLPs that maintain ease of production through established recombinant expression systems while gaining enhanced immunological properties.
3Adaptability or versatility
If chimeric VLPs are created to present non-self-assembling epitopes, then vaccine application is expanded, but the size limitations of insertable epitopes remain
Solution Approach 1:
The invention performs preliminary action by pre-optimizing the HI loop region design before epitope insertion. The HI loop is prepared as a ready-made insertion site with appropriate spacing and structural characteristics, allowing diverse epitopes of varying sizes to be inserted without requiring redesign of the entire VLP structure. This preliminary preparation enables expansion of vaccine applications while avoiding size constraints.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chimeric VLPs demonstrate enhanced antibody and cellular immune responses, effectively activating dendritic cells and inducing cytokine production, thereby offering a potent vaccine platform for various antigens, including tumor and pathogen-specific antigens.
Implementation Method 1
The VLPs of the present invention activate antigen presenting cells (APCs) due to its particulate structure and inherent properties to activate innate immune response
Implementation Method 2
The creation of chimeric papillomavirus VLPs with a L1 protein that includes negatively charged amino acids, specifically in the HI loop, and the conjugation of these VLPs with target antigens using a polyionic approach
Data Source
AI summary
The present invention relates to the field of vaccines. In particular, the present invention provides compositions and methods relating to virus-like particle (VLP) vaccines. In one embodiment, a chimeric papillomavirus virus-like particle (VLP) comprises the L1 protein, wherein the HI loop of the L1 protein comprises negatively charged amino acids. In a more specific embodiment, a chimeric bovine papillomavirus VLP comprises the L1 protein, wherein the amino acid sequence EEEEEEEEC is inserted into the HI loop of the L1 protein.